Loading organizations...
MBL Venture Capital is the investment arm of Medical & Biological Laboratories Co., supporting ventures from seed to later stages. It focuses on biotechnology, life science, drug discovery, and regenerative medicine sectors. The firm also invests in related IT applications, including bioinformatics, medical diagnostics, devices, and specialized medical services, fostering comprehensive innovation across the health sector.
Established in Japan in 2000, MBL Venture Capital originated from its parent company's deep biological research expertise. It was formed to back enterprises driving scientific and technological advancements in critical health domains. This corporate venture initiative leverages the parent organization's connection to nurture nascent life science and medical technology companies.
The firm's portfolio comprises emerging companies developing advanced solutions in its specialized investment sectors, from academic spin-offs to established startups. MBL Venture Capital is committed to advancing scientific understanding and enhancing global healthcare. Its vision involves translating groundbreaking research into practical applications, cultivating a vibrant ecosystem for biological innovation.
MBL Venture Capital has 1 tracked investment across 1 company. The latest tracked deal is $12.0M Series A in Sentien Biotechnologies in April 2017.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 1, 2017 | Sentien Biotechnologies | $12.0M Series A | Mission BioCapital, Martin Heidecker | AMR Action Fund, Giacomo Chiesi, Mass Medical Angels |